Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -0.86%94 Altman Z-Score is 12.81 as of Jul. 22, 2026, which is 8% above its 10-year median of 11.91. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 94/100 and a GF Value™ of ₹590.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 89.66% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 12.38 is strong.
Metropolis Healthcare has a Altman Z-Score of 12.81, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Metropolis Healthcare's Altman Z-Score or its related term are showing as below:
NSE:METROPOLIS'
s Altman Z-Score Range Over the Past 10 Years
Min: 9.51 Med: 11.91 Max: 26.21
Current: 12.38
During the past 11 years, Metropolis Healthcare's highest Altman Z-Score was 26.21. The lowest was 9.51. And the median was 11.91.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Metropolis Healthcare Altman Z-Score Related Terms
Metropolis Healthcare Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Metropolis Healthcare (NSE:METROPOLIS) has a Altman Z-Score of 12.81 as of Jul. 22, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Metropolis Healthcare and its competitors. This is near median its historical median of 11.91. Over the past decade, Metropolis Healthcare's Altman Z-Score has ranged from 9.51 to 26.21. According to the industry distribution chart, Metropolis Healthcare ranks #21 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 10.3%.
Is Metropolis Healthcare's Altman Z-Score too high?
Metropolis Healthcare's current Altman Z-Score of 12.81 is near median its 10-year median of 11.91. Over the past 10 years, this metric has ranged from a low of 9.51 to a high of 26.21. The Medical Diagnostics & Research industry median Altman Z-Score is 2.44. Metropolis Healthcare's value of 12.81 is 425% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #21 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #21 out of 203 companies for Altman Z-Score. This places Metropolis Healthcare in the top 10% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.44. Metropolis Healthcare's value of 12.81 is 425% above this benchmark. Historically, Metropolis Healthcare's own Altman Z-Score has ranged from 9.51 to 26.21 over the past decade. While the company's 10-year median is 11.91 vs. the industry median of 2.44, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.44, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current Altman Z-Score of 12.81 is 425% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current Altman Z-Score is 12.81, which is near median its own 10-year median of 11.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹590.00, compared to a current price of ₹568.80 — trading 3.6% below its estimated fair value. The current Altman Z-Score is 12.81, which is near median its 10-year median of 11.91 and 425% above the Medical Diagnostics & Research industry median of 2.44. Metropolis Healthcare's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Altman Z-Score is 12.81 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹568.80 is trading 3.6% below its estimated GF Value™ of ₹590.00.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Altman Z-Score: 12.81 (near median its 10-year median of 11.91)
GF Value™: ₹590.00 vs. price of ₹568.80 (3.6% below fair value)
Industry Position: 425% above the Medical Diagnostics & Research median (#21 of 203)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
94GF Score
Get the complete analysis for NSE:METROPOLIS
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
